Recital 5, Regulation (EU) 2025/1466

In forcesince 22 Jul 2025

The Eudravigilance database is the system for managing and analysing information on adverse reactions to medicines that have been authorised or are being studied in clinical trials. The European Medicines Agency (‘the Agency’) and national competent authorities continuously monitor the data in the Eudravigilance database. The database is also accessible to marketing authorisation holders to the extent necessary for them to fulfil their pharmacovigilance obligations. Based on the experience acquired from marketing authorisation holders’ monitoring of the data in the Eudravigilance database, the requirements for marketing authorisation holders should be clarified, including the requirements for signal validation and subsequent notification to the Agency and national competent authorities.